|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 11/00 | (2006.01) | ||
| C07K 16/22 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Patento numeris | 2918288 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15154393.1 |
| Europos patento paraiškos padavimo data | 2007-10-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-09-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-08-16 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 827933 P | 2006-10-03 | US |
| (72) |
Streisand, James B., US
Roberts, Jesse D., US
|
| (73) |
Genzyme Corporation,
500 Kendall Street, Cambridge, MA 02142,
US
The General Hospital Corporation, Massachusetts General Hospital 55 Fruit Street, Boston, MA 02114, US |
| (54) | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |